Oregon Revised Statutes Chapter 735 § 735.534 — Claim

Claim reimbursement; maximum allowable costs; documentation; complaints; rules. (1) As used in this section: (a) “Conflict of interest” means: (A) Present employment, ownership or control by a covered entity, pharmaceutical manufacturer, pharmacy benefit manager or health benefit plan as defined in ORS 743B.005; or (B) Third party employment, ownership or control by a covered entity, pharmaceutical manufacturer, pharmacy benefit manager or health benefit plan as defined in ORS 743B.005. (b) “Covered entity” means a covered entity as defined in 42 U.S.C. 256b(a)(4)(A) and (C) to (G). (c)(A) “Generally available for purchase” means a drug is available for purchase in this state by a pharmacy from a national or regional wholesaler at the time a claim for reimbursement is submitted by a network pharmacy. (B) A drug is not “generally available for purchase” if the drug: (i) May be dispensed only in a hospital or inpatient care facility; (ii) Is unavailable due to a shortage of the product or an ingredient; (iii) Is available to a pharmacy at a price that is at or below the maximum allowable cost only if purchased in substantial quantities that are inconsistent with the business needs of a pharmacy; (iv) Is sold at a discount due to a short expiration date on the drug; or (v) Is the subject of an active or pending recall. (d) “List” means the list of drugs for which maximum allowable costs have been established. (e) “Maximum allowable cost” means the maximum amount that a pharmacy benefit manager will reimburse a pharmacy for the cost of a drug. (f) “Multiple source drug” means a therapeutically equivalent drug that is available from at least two manufacturers. (g) “Therapeutically equivalent” has the meaning given that term in ORS 689.515. (2) A pharmacy benefit manager licensed under ORS 735.532: (a) May not place a drug on a list unless there are at least two multiple source drugs, or at least one generic drug generally available for purchase. (b) Shall ensure that all drugs on a list are generally available for purchase. (c) Shall ensure that no drug on a list is obsolete. (d) Shall make available to each network pharmacy at the beginning of the term of a contract, and upon renewal of a contract, the specific authoritative industry sources, other than proprietary sources, the pharmacy benefit manager uses to determine the maximum allowable cost set by the pharmacy benefit manager. (e) Shall make a list available to a network pharmacy upon request in a format that: (A) Is electronic; (B) Is computer accessible and searchable; (C) Identifies all drugs for which maximum allowable costs have been established; and (D) For each drug specifies: (i) The national drug code; and (ii) The maximum allowable cost. (f) Shall update each list maintained by the pharmacy benefit manager every seven business days and make the updated lists, including all changes in the price of drugs, available to network pharmacies in the format described in paragraph (e) of this subsection. (g) Shall ensure that dispensing fees are not included in the calculation of maximum allowable cost. (h) May not reimburse a 340B pharmacy differently than any other network pharmacy based on its status as a 340B pharmacy. (i) Shall comply with the provisions of ORS 743A.062. (j) May not retroactively deny or reduce payment on a claim for reimbursement of the cost of services after the claim has been adjudicated by the pharmacy benefit manager unless the: (A) Adjudicated claim was submitted fraudulently; (B) Pharmacy benefit manager’s payment on the adjudicated claim was incorrect because the pharmacy had already been paid for the services; (C) Services were improperly rendered by the pharmacy in violation of state or federal law; or (D) Payment was incorrect due to an error that the pharmacy and pharmacy benefit manager agree was a clerical error. (k) May not impose a fee on a pharmacy after the point of sale. (L) Shall provide notice to a pharmacy of any claim for reimbursement of the cost of a prescription drug that is denied or reduced. The notice shall identify the specific disaggregated claim that was denied or reduced and a detailed explanation for why the specific claim was denied or reduced. (m) May require a covered entity to submit a claim for reimbursement of a prescription drug that includes a modifier or other indicator that the drug is a 340B drug unless: (A) The covered entity has submitted 340B drug data to a third party clearinghouse of the covered entity’s choosing that: (i) Requests and receives claim data, including pharmacy claims, from covered entities; (ii) Ensures that claim data submissions by covered entities are complete and accurate; (iii) Provides manufacturers with validation of a 340B drug that includes requested claim information submitted by a covered entity and allows pharmaceutical manufacturers to identify units of a 340B drug that may be subjec